Pain symptomology, functional impact, and treatment of people with Neurofibromatosis type 1

References

• Anderson JL, Gutmann DH. Neurofibromatosis type 1. Handb Clin Neurol. 2015;132:75–86. doi:10.1016/B978-0-444-62702-5.00004-426564071
   PubMedGoogle Scholar
• Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol. 2014;13(8):834–843. doi:10.1016/S1474-4422(14)70063-825030515
   PubMed Web of Science ®Google Scholar
• Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ. Neurofibromatosis type 1. Nat Rev Dis Primers. 2017;3:17004. doi:10.1038/nrdp.2017.428230061
   PubMed Web of Science ®Google Scholar
• Brems H, Beert E, de Ravel T, Legius E. Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. Lancet Oncol. 2009;10(5):508–515. doi:10.1016/S1470-2045(09)70033-619410195
   PubMed Web of Science ®Google Scholar
• Tucker T, Friedman JM, Friedrich RE, Wenzel R, Funsterer C, Mautner VF. Longitudinal study of neurofibromatosis 1 associated plexiform neurofibromas. J Med Genet. 2009;46(2):81–85. doi:10.1136/jmg.2008.06105118930997
   PubMed Web of Science ®Google Scholar
• Wolters PL, Burns KM, Martin S, et al. Pain interference in youth with neurofibromatosis type 1 and plexiform neurofibromas and relation to disease severity, social-emotional functioning, and quality of life. Am J Med Genet A. 2015;167A(9):2103–2113. doi:10.1002/ajmg.a.3712325976979
   PubMed Web of Science ®Google Scholar
• Merker VL, Esparza S, Smith MJ, Stemmer-Rachamimov A, Plotkin SR. Clinical features of schwannomatosis: a retrospective analysis of 87 patients. Oncologist. 2012;17(10):1317–1322. doi:10.1634/theoncologist.2012-016222927469
   PubMed Web of Science ®Google Scholar
• Ferner RE, Thomas M, Mercer G, et al. Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire. Health Qual Life Outcomes. 2017;15(34).28109278
   PubMed Web of Science ®Google Scholar
• Creange A, Zeller J, Rostaing-Rigattieri S, et al. Neurological complications of neurofibromatosis type 1 in adulthood. Brain. 1999;122(Pt 3):473–481. doi:10.1093/brain/122.3.47310094256
   PubMed Web of Science ®Google Scholar
• Jeong YH, Choi EJ, Nahm FS. Concurrence of malignant peripheral nerve sheath tumor at the site of complex regional pain syndrome type 1 – a case report. Korean J Pain. 2013;26(2):160–163. doi:10.3344/kjp.2013.26.2.16023614078
   PubMedGoogle Scholar
• Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R. A single-question screening test for drug use in primary care. Arch Intern Med. 2010;170(13):1155–1160. doi:10.1001/archinternmed.2010.14020625025
   PubMed Web of Science ®Google Scholar
• Cleeland CS, Ryan K. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994;23(2):129–138.8080219
   PubMedGoogle Scholar
• Krebs EE, Bair MJ, Damush TM, Tu W, Wu J, Kroenke K. Comparative responsiveness of pain outcome measures among primary care patients with musculoskeletal pain. Med Care. 2010;48(11):1007–1014. doi:10.1097/MLR.0b013e3181eaf83520856144
   PubMed Web of Science ®Google Scholar
• Barry DT, Savant JD, Beitel M, et al. Use of conventional, complementary, and alternative treatments for pain among individuals seeking primary care treatment with buprenorphine-naloxone. J Addict Med. 2012;6(4):274–279. doi:10.1097/ADM.0b013e31826d1df323041680
   PubMed Web of Science ®Google Scholar
• Trochim W, Donnelly JP, Arora K. Research Methods: The Essential Knowledge Base. Boston, MA: Nelson Education; 2015.
   Google Scholar
• Bicudo NP, de Menezes Neto BF, da Silva de Avo LR, Germano CM, Melo DG. Quality of life in adults with Neurofibromatosis 1 in Brazil. J Genet Couns. 2016;25(5):1063–1074. doi:10.1007/s10897-016-9939-826944915
   PubMed Web of Science ®Google Scholar
• Rasmussen SA, Yang Q, Friedman JM. Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am J Hum Genet. 2001;68(5):1110–1118. doi:10.1086/32012111283797
   PubMed Web of Science ®Google Scholar
• Jett K, Friedman JM. Clinical and genetic aspects of neurofibromatosis 1. Genet Med. 2010;12(1):1–11. doi:10.1097/GIM.0b013e3181bf15e320027112
   PubMed Web of Science ®Google Scholar
• Daubresse M, Chang HY, Yu Y, et al. Ambulatory diagnosis and treatment of nonmalignant pain in the United States, 2000-2010. Med Care. 2013;51(10):870–878. doi:10.1097/MLR.0b013e3182a95d8624025657
   PubMed Web of Science ®Google Scholar
• Meldrum ML. A capsule history of pain management. JAMA. 2003;290(18):2470–2475. doi:10.1001/jama.290.18.247014612484
   PubMed Web of Science ®Google Scholar
• Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011;14(2):145–161.21412369
   PubMed Web of Science ®Google Scholar
• Thomas DA, Maslin B, Legler A, Springer E, Asgerally A, Vadivelu N. Role of alternative therapies for chronic pain syndromes. Curr Pain Headache Rep. 2016;20(5):29. doi:10.1007/s11916-016-0562-z27038968
   PubMed Web of Science ®Google Scholar
• Perry R, Leach V, Davies P, Penfold C, Ness A, Churchill R. An overview of systematic reviews of complementary and alternative therapies for fibromyalgia using both AMSTAR and ROBIS as quality assessment tools. Syst Rev. 2017;6(1):97. doi:10.1186/s13643-017-0487-628506257
   PubMed Web of Science ®Google Scholar
• Zautra AJ, Davis MC, Reich JW, et al. Comparison of cognitive behavioral and mindfulness meditation interventions on adaptation to rheumatoid arthritis for patients with and without history of recurrent depression. J Consult Clin Psychol. 2008;76(3):408–421. doi:10.1037/0022-006X.76.3.40818540734
   PubMed Web of Science ®Google Scholar
• Martin S, Wolters PL, Toledo-Tamula MA, et al. Acceptance and commitment therapy in youth with neurofibromatosis type 1 (NF1) and chronic pain and their parents: a pilot study of feasibility and preliminary efficacy. Am J Med Genet A. 2016;170(6):1462–1470. doi:10.1002/ajmg.a.3762327021207
   PubMed Web of Science ®Google Scholar
• Sharp LM, Frankel J. Respondent burden: a test of some common assumptions. Public Opin Q. 1983;47:1. doi:10.1086/268765
   Web of Science ®Google Scholar
• Porter SR, Whitcomb ME, Weitzer WH. Multiple surveys of students and survey fatigue. New Directions Institutional Res. 2004;2004(121):63–73. doi:10.1002/(ISSN)1536-075X
   Google Scholar
• Zhu X, Smith RA, Parrott RL. Living with a rare health condition: the influence of a support community and public stigma on communication, stress, and available support. J Appl Commun Res. 2017;45(2):179–198. doi:10.1080/00909882.2017.128829229398734
   PubMed Web of Science ®Google Scholar
• Pescosolido BA, Martin JK, McLeod JD, Rogers A. Handbook of the Sociology of Health, Illness, and Healing: A Blueprint for the 21st Century. New York (NY): Springer-Verlag; 2011.
   Google Scholar
• Joachim G, Acorn S. Life with a rare chronic disease: the Scleroderma experience. J Adv Nurs. 2003;42(6):598–606.12787233
   PubMed Web of Science ®Google Scholar